Analysts Offer Predictions for PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ProQR Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will earn ($0.36) per share for the year. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

PRQR has been the topic of several other reports. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Oppenheimer started coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Chardan Capital reiterated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $2.23 on Wednesday. The stock has a market cap of $182.15 million, a PE ratio of -6.97 and a beta of 0.30. The firm has a fifty day moving average price of $3.03 and a 200 day moving average price of $2.55. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. The company had revenue of $4.22 million during the quarter, compared to analyst estimates of $4.75 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently bought and sold shares of PRQR. Ballentine Partners LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $61,000. OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. increased its stake in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after purchasing an additional 51,663 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).